Stockscreener 앱 받기
9.34
0.86%
0.08
시장 영업 전:
9.22
-0.12
-1.28%
Novavax Inc 주식(NVAX)의 최신 뉴스
Novavax Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates - AD HOC NEWS
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
NVAX SEC FilingsNovavax Inc 10-K, 10-Q, 8-K Forms - Stock Titan
(NVAX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Novavax Inc. stock rises Monday, still underperforms market - MarketWatch
Novavax Q2 2025 Earnings Preview - MSN
Wall Street Recap: Can Novavax Inc stock outperform in a bear marketTrade Entry Report & AI Driven Stock Price Forecasts - baoquankhu1.vn
NVAX Technical Analysis | Trend, Signals & Chart Patterns | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Novavax Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Novavax Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q3 Earnings Estimate for Novavax Issued By Zacks Research - MarketBeat
2 Healthcare Stocks to Target This Week and 1 That Underwhelm - The Globe and Mail
Assessing Novavax (NVAX) Valuation As Licensing Income And COVID Momentum Shape Expectations - Yahoo Finance
Aug Selloffs: Is Novavax Inc benefiting from interest rate changesMarket Growth Report & Entry and Exit Point Strategies - baoquankhu1.vn
NVAX stock rises overnight ahead of Q4 print with Pfizer tailwinds — analyst warns of 20% crash - MSN
Novavax (NVAX) Shares Drop 1.23%: Key Information to Note - Bitget
Novavax (NVAX) Stock Moves -1.23%: What You Should Know - Yahoo! Finance Canada
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Therapeutics Sector Q4 Results: Revenue Beats Amid Market Stability - IndexBox
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Is trending stock Novavax, Inc. (NVAX) a buy now? - MSN
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NASDAQ:NVAX) Trading 7.6% HigherShould You Buy? - MarketBeat
Here’s What You Should Understand Besides the Reason Novavax, Inc. (NVAX) is Gaining Attention - Bitget
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - Yahoo Finance
DC InnoNovavax cancels Covid-19 vaccine contract | Oxiwear is going global - The Business Journals
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Farallon Capital Management LLC Purchases 764,000 Shares of Novavax, Inc. $NVAX - MarketBeat
Nuvaxovid (Novavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - Yahoo Finance
How (NVAX) Movements Inform Risk Allocation Models - Stock Traders Daily
FDA to Mandate Placebo-Controlled Trials for New Vaccines - MSN
Jefferies Maintains Buy on Novavax, Inc. (NVAX) March 2026 - Meyka
BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT - MSN
Novavax (NVAX) director John W. Shiver converts 7,947 RSUs into stock - Stock Titan
Jefferies reiterates Buy on Novavax stock, cites adjuvant platform By Investing.com - Investing.com India
Jefferies reiterates Buy on Novavax stock, cites adjuvant platform - Investing.com
Assessing Novavax (NVAX) Valuation After Strong 2025 Results And Return To Profitability - simplywall.st
Novavax (NASDAQ:NVAX) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Novavax Q4 earnings preview: Wall Street expects wider losses amid diversification efforts - MSN
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement - MSN
Novavax stock hits over 1-year high: Is Sanofi’s flu-COVID shot the post-pandemic growth driver? - MSN
The 7 Most Hated Stocks on Wall Street Today | Investing - Money/ US News
NVAX: Pivot to platform partnerships and innovation drives growth, with profitability targeted by 2028 - TradingView
Novavax (NVAX) EVP granted 139,500 non-statutory stock options - Stock Titan
Novavax Inc. (NVAX) legal chief updates 152,000-share stock option terms - Stock Titan
Novavax (NVAX) EVP granted 177,500 options with revised terms - Stock Titan
Therapeutics Companies Exceed Q4 2025 Revenue Estimates, Led by Novavax and AmgenNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Novavax (NVAX) CEO updates exercise price on 551,500 stock options - Stock Titan
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling - MSN
NOVAVAX INC (NASDAQ:NVAX) Screens as a Minervini-Style High-Growth Momentum Candidate - ChartMill
How Investors Are Reacting To Novavax (NVAX) Swinging From Losses To Profits On Vaccine Revenue - simplywall.st
Update Recap: Can Novavax Inc. stock maintain growth trajectory2025 Stock Rankings & High Conviction Trade Alerts - Naître et grandir
NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology - Stocktwits
Assessing Novavax (NVAX) Valuation After Strong Earnings Beat And Return To Profitability - simplywall.st
Novavax (NVAX) CFO reports RSU vesting and 20,850 shares withheld for taxes - Stock Titan
Novavax (NVAX) EVP Elaine O'Hara nets shares from RSU vesting and tax withholding - Stock Titan
Novavax (NVAX) legal chief logs RSU vesting and tax share withholding - Stock Titan
[Form 4] NOVAVAX INC Insider Trading Activity - Stock Titan
Novavax (NASDAQ: NVAX) CEO gets RSUs; shares withheld for taxes - Stock Titan
1.82%
자본화:
|
볼륨(24시간):